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difference in freedom from MALE and DFA patency. (N.S.)
CONCLUSION The results of stenting for in stent restenosis of SFA
with jailed DFA were favorable than ballooning and the 12 month fate
of DFA was acceptable in this study.
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BACKGROUND Ectatic and aneurysmal iliac arteries adversely affect
the treatment and long-term results of EVAR. Objective of the study is
to evaluate the use of novel technology to treat complex aortic
aneurysms involving iliac arteries. We reviewed our ﬁrst experience
with an unique endoprosthesis which is designed to treat aneurysms
by ﬁlling the aneurysm sac with a quick-setting polymer. Polymer is
contained in endobag surrounding the endoprothesis. The ﬁlled
endobags obliterate the aneurysm sac while providing support and
stability to the ﬂow lumens. With the new technology aneurysmal
iliac arteries are treated keeping internal iliac arteries patent.METHODS Patients with aorto-iliac aneurysms treated in our center
using the Nellix (Endologix, Inc.) endograft were reviewed. Patients
were treated in catheterization laboratory under regional or general
anaesthesia using femoral artery approach. Analyses were conducted
in accordance with the endovascular aneurysm reporting standards.
Follow-up studies accrued at discharge, one, 6, and 12 months, and
included computed tomography angiography and duplex ultrasound
angiography scans, and ﬂat plate radiography.
S52 J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 5 , N O . 1 7 , S U P P L S , 2 0 1 5RESULTS From 2008 to 2015 twenty patients with combined aortic
aneurysm and ectactic or aneurysmal common iliac arteries were
treated. The mean abdominal aortic aneurysm (AAA) size was 5.8 cm
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to 43mm). All patients received follow-up exams with mean follow-up
2.5 years. Bilateral CIA was present in 80% (16/20) of patients. Tech-
nical success was 100% with no procedure related complications. All
aneurysms were treated successfully. The mean implantation time
was 52+24 minutes (range, 35 to 98 minutes). There was no periop-
erative mortality. No internal iliac arteries were lost acutely or
occluded during follow-up. There were no ruptures or conversions in
this cohort group. Two patients required secondary interventions.CONCLUSION This novel sac-ﬁlling technology has made it techni-
cally feasible to preserve hypogastric artery in the setting of common
iliac artery and abdominal aortic aneurysm. High technical success,
simple procedure and low secondary intervention rate are encour-
aging. These advances have the potential to markedly increase the
number of patients treated and diminish complications associated
with conventional management of complex aneurysms.TCTAP A-100
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BACKGROUND Clinical outcome of femoropopliteal (FP) stenting
with drug eluting stents (DES) for diabetic patient remains unclear.
